Market capitalization | $1.01b |
Enterprise Value | $977.62m |
PER (TTM) P/E ratio | 14.69 |
EV/FCF (TTM) EV/FCF | 29.45 |
EV/Sales (TTM) EV/Sales | 2.92 |
P/S ratio (TTM) P/S ratio | 3.01 |
P/B ratio (TTM) P/B ratio | 6.46 |
Sales growth (TTM) Sales growth | 19.20% |
Turnover (TTM) Turnover | $334.51m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
6 Analysts have issued a MiMedx Group, Inc. forecast:
6 Analysts have issued a MiMedx Group, Inc. forecast:
Dec '23 | |
Current assets | 164 164 |
Fixed assets | 75 75 |
Total assets | 239 239 |
Dec '23 | |
Equity | 143 143 |
Debt capital | 96 96 |
Total capital | 239 239 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.
Head office | United States |
CEO | Joe Capper |
Employees | 895 |
Founded | 1985 |
Website | www.mimedx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.